IFNA1 and laryngotracheoesophageal cleft: However, among the articles selected based on the eligible criteria in this study, only two articles reported outcomes other than HCC by response to antiviral therapy: unchanged incidence of malignancy other than HCC by response to IFN44 and decreased progression to LC in patients without LC before IFN therapy by SVR to IFN45.